ArticleScientific reports2024
All organic nanomedicine for PDT-PTT combination therapy of cancer cells in hypoxia.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A Compositionally Tunable Micelle Platform for Integrated Photoacoustic Imaging, Direct Visual Guidance, and Photothermal Therapy of Solid Tumors.ACS applied nano materials · 2026Article
- 2D MoSNano convergence · 2026Article
- A paradigm shift from penetration: Material-based solutions for multidimensional spatiotemporal, hypoxic, and optical challenges in cutaneous photodynamic therapy.Materials today. Bio · 2026Review
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
- Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer.Frontiers in pharmacology · 2026Review
- Research trends and hotspots of upconversion nanoparticles for drug delivery and biomedical targeting in photodynamic therapy.Discover nano · 2025Review
- Magnetic Nanoparticles: Synthesis and Applications in Life Sciences.ChemistryOpen · 2025Review
- Curcumin-Loaded Nanomaterials as Carriers for Photodynamic Therapy Against Cancers.Gels (Basel, Switzerland) · 2025Review
- Article
- ICG/MnOLasers in medical science · 2025Article
- Enhanced Intracellular IR780 Delivery by Acidity-Triggered PEG-Detachable Hybrid Nanoparticles to Augment Photodynamic and Photothermal Combination Therapy for Melanoma Treatment.ACS applied bio materials · 2025Article
- Recent Advances in Nano-Drug Delivery Strategies for Chalcogen-Based Therapeutic Agents in Cancer Phototherapy.International journal of molecular sciences · 2025Review
- Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms.Pharmaceutics · 2025Review
- Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.Lipids in health and disease · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Photodynamic and photothermal therapies are promising treatments for cancer, dermatological, and ophthalmological conditions. However, photodynamic therapy (PDT) is less effective in oxygen-deficient tumor environments. Combining PDT with photothermal therapy (PTT) can enhance oxygen supply and treatment efficacy. Inorganic PTT agents pose toxicity risks, limiting their clinical use despite their high performance. In this study, we developed a novel nanomedicine integrating an all-organic photothermal agent and an organic photosensitizer, creating a colocalized nanoplatform to enhance phototherapy efficacy in cancer treatment. PTT nanoparticles (NPs) were synthesized through a thermal phase transition of organic chromophores, demonstrating superior photothermal properties and photostability. Utilizing this nanoplatform, we devised 'Combi NPs' for combined PDT-PTT nanomedicine. Tests on A549 cancer cell lines have revealed that Combi NPs exhibit superior cytotoxicity and induce apoptosis in hypoxic conditions, outperforming PTT-only NPs. The all-organic Combi NPs show significant potential for clinical cancer phototherapy in hypoxic microenvironments, potentially mitigating long-term nanomedicine accumulation and associated toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.